Pharma Boardroom: Interview with Deana Mohr-Haralampieva
05-11-2024 – With its therapy rooted in tissue engineering, MUVON is developing a low-risk, minimally invasive treatment that uses the patient’s own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle to treat stress urinary incontinence (SUI).
"Not only was safety confirmed, but we also saw encouraging early signs of efficacy, such as increased muscle volume, strength, and significant improvements in the patients’ quality of life", shares Deana, commenting on the results of the phase 1/2 clinical trial.
The team is now conducting a phase II clinical trial at University Hospital Zurich, where the earlier trial was placed, with support from the Wyss Zurich Translational Centre.
"We anticipate interim results in the next few months, with the final readout expected by next summer. These results will be critical as they will guide our path towards pivotal trials in both Europe and the US", shares Deana.
Looking ahead, Deana and her team are looking at:
- Advancing their clinical programs, with a specific focus on expanding into the European and US markets
- Preparing commercial readiness, for example, through strategic partnerships, and
- Expanding the therapeutic applications by exploring additional indications beyond their current focus
